• Login
    ARAN - Access to Research at NUI Galway
    View Item 
    •   ARAN Home
    • Support Services
    • Externally hosted open access publications with NUI Galway authors (2)
    • View Item
    •   ARAN Home
    • Support Services
    • Externally hosted open access publications with NUI Galway authors (2)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ARANCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsTypesThis CollectionBy Issue DateAuthorsTitlesSubjectsTypes

    My Account

    LoginRegister

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Help

    How to submit and FAQs

    Highly sensitive b cell analysis predicts response to rituximab therapy in rheumatoid arthritis

    Thumbnail
    View/Open
    Full Text
    Date
    2008-10-01
    Author
    Dass, Shouvik
    Rawstron, Andy C.
    Vital, Edward M.
    Henshaw, Karen
    McGonagle, Dennis
    Emery, Paul
    Metadata
    Show full item record
    Usage
    This item's downloads: 0 (view details)
    
    Recommended Citation
    Dass, Shouvik; Rawstron, Andy C. Vital, Edward M.; Henshaw, Karen; McGonagle, Dennis; Emery, Paul (2008). Highly sensitive b cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis & Rheumatism 58 (10), 2993-2999
    Published Version
    http://onlinelibrary.wiley.com/doi/10.1002/art.23902/pdf
    Abstract
    Objective. In rheumatoid arthritis (RA), B cell depletion occurs in all patients treated with rituximab, but the clinical responses to rituximab are variable. A highly sensitive assay was used to test the hypothesis that B cell depletion is variable, and that incomplete depletion leads to a poorer outcome. Methods. Sixty patients with active RA unresponsive to anti-tumor necrosis factor agents received two I-gram infusions of rituximab. B cell numbers were measured by highly sensitive flow cytometry before and after each infusion and at 3-month intervals thereafter. A reduction in B cell levels below 0.0001 x 10(9)/liter was defined as complete depletion (compared with 0.05 x 109/liter by conventional cytometry). Clinical responses were measured using the European League Against Rheumatism (EULAR) criteria. Results. At 6 months, 92% of patients had a moderate-to-good clinical response according to the EULAR criteria. B cells were detected in 63% of patients after the first infusion of rituximab (median level 0.0009 x 10(9)/liter [range <0.0001-0.0015 x 10(9)/liter), and these patients had poorer clinical outcomes than patients with complete depletion. At 9 months, 82% of patients with complete depletion had a moderate-to-good EULAR response, compared with 43% of those with partial depletion (P = 0.01). At 12 months, 59% of complete responders had a moderate-to-good EULAR response, compared with 21% of those with partial depletion (P = 0.01). Patients in whom B cells were depleted only after the second infusion did no better than those in whom depletion was never complete and had poorer clinical outcomes than those in whom depletion was initially complete. Conclusion. This study is the first to show, using a highly sensitive analysis, that rituximab therapy is associated with variable diminution in B cell numbers. A lack of complete depletion of B cells after I infusion was associated with a poorer outcome.
    URI
    http://hdl.handle.net/10379/11068
    Collections
    • Externally hosted open access publications with NUI Galway authors (2)
    • Copyright @ NUI Galway 2016
    • Library
    • NUI Galway